BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 19207950)

  • 1. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
    Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B
    Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
    Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
    Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH).
    Fritzsche FR; Bode PK; Moch H; Kristiansen G; Varga Z; Bode B
    Am J Surg Pathol; 2010 Aug; 34(8):1180-5. PubMed ID: 20661016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma.
    Ramieri MT; Murari R; Botti C; Pica E; Zotti G; Alo PL
    Anticancer Res; 2010 Apr; 30(4):1287-92. PubMed ID: 20530441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of silver-enhanced in situ hybridization for evaluating HER2 gene status in invasive breast carcinoma: a comparative study.
    Lee Y; Ryu Y; Jeong H; Chang H; Kim Y; Kim A
    Arch Med Res; 2012 Feb; 43(2):139-44. PubMed ID: 22475781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections?
    Sumiyoshi K; Shibayama Y; Akashi S; Nohara T; Iwamoto M; Kobayashi T; Nishimura H; Yoshinaka R; Harada T; Tanigawa N
    Oncol Rep; 2006 Apr; 15(4):803-8. PubMed ID: 16525662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
    Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.
    Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
    Histopathology; 2012 May; 60(6):880-4. PubMed ID: 22320892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.
    Carbone A; Botti G; Gloghini A; Simone G; Truini M; Curcio MP; Gasparini P; Mangia A; Perin T; Salvi S; Testi A; Verderio P
    J Mol Diagn; 2008 Nov; 10(6):527-36. PubMed ID: 18832456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Automated silver-enhanced in situ hybridization detection assay for human epidermal growth factor receptor 2 gene status determination in breast cancer].
    Ying JM; Guo L; Liu XY; Qiu T; Lü N
    Zhonghua Yi Xue Za Zhi; 2010 Jun; 90(24):1674-7. PubMed ID: 20979875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: influence of poor tissue preservation.
    Schiavon BN; Jasani B; de Brot L; Vassallo J; Damascena A; Cirullo-Neto J; Ivanildo Neves J; Augusto Soares F; Gobbi H; Malagoli Rocha R
    Am J Surg Pathol; 2012 Oct; 36(10):1489-96. PubMed ID: 22982892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.
    Dietel M; Ellis IO; Höfler H; Kreipe H; Moch H; Dankof A; Kölble K; Kristiansen G
    Virchows Arch; 2007 Jul; 451(1):19-25. PubMed ID: 17562074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
    Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
    Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
    Yano T; Doi T; Ohtsu A; Boku N; Hashizume K; Nakanishi M; Ochiai A
    Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of HER2 gene amplification in breast cancer using dual-color silver enhanced in situ hybridization (dc- SISH) and comparison with fluorescence ISH (FISH).
    Unal B; Karaveli FS; Pestereli HE; Erdogan G
    Asian Pac J Cancer Prev; 2013; 14(10):6131-4. PubMed ID: 24289638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. Comparison of in situ hybridization methods.
    Sińczak-Kuta A; Tomaszewska R; Rudnicka-Sosin L; Okoń K; Stachura J
    Pol J Pathol; 2007; 58(1):41-50. PubMed ID: 17585541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas.
    Tafe LJ; Allen SF; Steinmetz HB; Dokus BA; Cook LJ; Marotti JD; Tsongalis GJ
    Exp Mol Pathol; 2014 Aug; 97(1):116-9. PubMed ID: 24927872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.